Research Article
The Study of Cost-Effectiveness of Rivaroxaban versus Warfarin in Patients with Atrial Fibrillation Who Developed Ischemic Stroke
Table 1
Direct and indirect costs of patients with atrial fibrillation treated with rivaroxaban and warfarin in 2019.
| Cost type | Costs items | Rivaroxaban | Warfarin | value | Mean (PPP$) | Mean (PPP$) |
| Direct medical costs | Physician visit | 162 | 176 | 0.25 | Medication | 1422 | 999 | <0.001 | Diagnosis and lab services | 33 | 217 | <0.001 | Physiotherapy and other services | 2425 | 2609 | 0.95 | Hospitalization | 845 | 889 | 0.59 | Direct nonmedical costs | Transportation, accommodation and meals | 856 | 799 | 0.59 | Indirect costs | Lost income | 19531 | 20864 | 0.005 | Total costs | 25275 | 26554 | 0.004 |
|
|
Medical equipment, complementary medicine. |